Evidence map›Paper›PMID 39002057›Full record

ArticleMolecular neurobiology2025

Impact and Interrelationships of Striatal Proteins, EPHB2, OPRM1, and PER2 on Mild Cognitive Impairment.

Nicole Bon Campomayor, Hee Jin Kim, Hyun Jun Lee, Leandro Val Sayson, Darlene Mae D Ortiz, Eunbi Cho, Dong Hyun Kim, Se Jin Jeon, Bung-Nyun Kim, Jae Hoon Cheong and 1 more

Abstract read
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nicole Bon CampomayorDepartment of Pharmacy, Uimyung Research Institute for Neuroscience, Sahmyook University, Hwarangro 815, Nowon-gu, Seoul, 01795, Republic of Korea.
Hee Jin KimDepartment of Pharmacy, Uimyung Research Institute for Neuroscience, Sahmyook University, Hwarangro 815, Nowon-gu, Seoul, 01795, Republic of Korea.
Hyun Jun LeeDepartment of Pharmacy, Uimyung Research Institute for Neuroscience, Sahmyook University, Hwarangro 815, Nowon-gu, Seoul, 01795, Republic of Korea.
Leandro Val SaysonDepartment of Pharmacy, Uimyung Research Institute for Neuroscience, Sahmyook University, Hwarangro 815, Nowon-gu, Seoul, 01795, Republic of Korea.
Darlene Mae D OrtizDepartment of Pharmacy, Uimyung Research Institute for Neuroscience, Sahmyook University, Hwarangro 815, Nowon-gu, Seoul, 01795, Republic of Korea.
Eunbi ChoDepartment of Pharmacology and Department of Advanced Translational Medicine, School of Medicine, Konkuk University, Seoul, 05029, Republic of Korea.
Dong Hyun KimDepartment of Pharmacology and Department of Advanced Translational Medicine, School of Medicine, Konkuk University, Seoul, 05029, Republic of Korea.
Se Jin JeonDepartment of Pharmacology, College of Medicine, Hallym University, Chuncheon, Gangwon, 24252, Republic of Korea.
Bung-Nyun KimDepartment of Psychiatry and Behavioral Science, College of Medicine, Seoul National University, Daehakro 101, Jongno-gu, Seoul, 03080, Republic of Korea.
Jae Hoon CheongSchool of Pharmacy, Jeonbuk National University, Baekje-daero 567, Jeonju-SiJeonju-si, Jeollabuk-do, 54896, Republic of Korea. cheongjh@jbnu.ac.kr.
Mikyung KimDepartment of Pharmacy, Uimyung Research Institute for Neuroscience, Sahmyook University, Hwarangro 815, Nowon-gu, Seoul, 01795, Republic of Korea. mkkim@syu.ac.kr.ORCID http://orcid.org/0000-0003-0524-1658

Funding

National Research Foundation (NRF) of Korea 2016R1D1A1B02010387National Research Foundation (NRF) of Korea 2020M3E5D9080791National Research Foundation (NRF) of Korea NRF-2021R1G1A1093620
6 · The paper itself

Abstract

With the global increase in life expectancy, there has been a rise in the incidence of cognitive impairments attributed to diverse etiologies. Notably, approximately 50% of individuals diagnosed with mild cognitive impairment (MCI) progress to dementia within 3 years. However, the precise mechanisms underlying MCI remain elusive. Therefore, this study aimed to elucidate potential mechanisms implicated in MCI utilizing Per2 knockout (KO) mice, which have previously been shown to have cognitive deficits. Behavioral (Y-maze, Barnes maze) and molecular (electrophysiology, RNA sequencing, western blot, and immunofluorescence) experiments were conducted in Per2 KO and wild-type (WT) mice. Per2 KO mice exhibited impaired spatial working memory in the Y-maze and Barnes maze. However, there were no significant group differences in hippocampal long-term potentiation (LTP) between Per2 KO and WT mice, whereas striatal LTP in Per2 KO mice was lower compared to WT mice. In RNA sequencing analysis, 58 genes were downregulated and 64 genes were upregulated in the striatum of Per2 KO mice compared to WT mice. Among the differentially expressed genes, four genes (Chrm2, EphB2, Htr1b, Oprm1) were identified. Optimal expression levels of EPHB2 and OPRM1 were found to significantly enhance cognitive performance in mice. Additionally, Per2 KO mice exhibited reduced EPHB2-NMDAR-LTP and OPRM-mTOR signaling, along with elevated amyloid beta (Aβ) levels, when compared to WT mice. However, these alterations were reversed upon administration of morphine treatment. Striatal OPRM1-mTOR signaling, EPHB2-NMDAR-LTP signaling, and Aβ expression levels may exert a combined effect on MCI under the control of Per2 expression.

Indexed as

Cognitive DysfunctionCorpus StriatumReceptor, EphB2Receptors, Opioid, muAnimalsHippocampusLong-Term PotentiationMaleMaze LearningMiceMice, Inbred C57BLMice, KnockoutEphb2 protein, mouseReceptor, EphB2Receptors, Opioid, muAmyloid betaEPHB2Mild cognitive impairmentOPRM1Per2

Identifiers

PMID39002057
PMCPMC11772528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.